Skip to main content
Top
Published in: Addiction Science & Clinical Practice 1/2015

Open Access 01-12-2015 | Research

Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder

Authors: Aaron D Fox, Jeronimo Maradiaga, Linda Weiss, Jennifer Sanchez, Joanna L Starrels, Chinazo O Cunningham

Published in: Addiction Science & Clinical Practice | Issue 1/2015

Login to get access

Abstract

Background

The United States has the highest rate of incarceration in the world (937 per 100,000 adults). Approximately one-third of heroin users pass through correctional facilities annually. Few receive medication assisted treatment (MAT; either methadone or buprenorphine) for opioid use disorder during incarceration, and nearly three-quarters relapse to heroin use within 3 months of release. This qualitative study investigated barriers to and facilitators of buprenorphine maintenance treatment (BMT) following release from incarceration (“re-entry”).

Methods

We conducted 21 semistructured interviews of former inmates with opioid use disorder recruited from addiction treatment settings. Interviews were audio-recorded, transcribed, and analyzed using a grounded theory approach. Themes that emerged upon iterative readings of transcripts were discussed by the research team.

Results

Participants reported adverse re-entry conditions, including persistent exposure to drug use and stressful life events, which were perceived to contribute to opioid relapse and affected addiction treatment decisions during re-entry. Themes that emerged relating to BMT included: 1) reliance on willpower; 2) fear of dependency on medications; 3) variable exposure to buprenorphine; and 4) acceptability of BMT following relapse. Willpower was perceived to be more important for recovery than medications. Many participants experienced painful withdrawal from methadone during incarceration and were fearful that using MAT would lead to opioid tolerance and painful withdrawal again in the future. Participants reported both positive and negative experiences taking illicit buprenorphine, which affected interest in BMT. Overall, BMT was perceived to be a good treatment option for opioid use disorder that could reduce the risk of re-incarceration.

Conclusions

BMT was perceived to be acceptable, but former inmates with opioid use disorder may be reluctant to utilize BMT upon re-entry. Factors limiting utilization of BMT could be mitigated though policy change or interventions. Policies of the criminal justice system (e.g., forced detoxification) may be dissuading former inmates from utilizing effective treatments for opioid use disorder. Interventions that improve education and access to BMT for former inmates with opioid use disorder could facilitate entrance into treatment. Both policy changes and interventions are urgently needed to reduce the negative consequences of opioid relapse following re-entry.
Literature
1.
go back to reference Glaze LE, Parks E. Correctional populations in the United States, 2011. Washington DC: U.S. Department of Justice; 2012. Glaze LE, Parks E. Correctional populations in the United States, 2011. Washington DC: U.S. Department of Justice; 2012.
2.
go back to reference Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 2004 (revised 1/19/07). Washington, DC: U.S. Department of Justice; 2006. Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisoners, 2004 (revised 1/19/07). Washington, DC: U.S. Department of Justice; 2006.
4.
go back to reference Karberg JC, James DJ. Substance dependence, abuse, and treatment of jail inmates, 2002. Washington DC: U.S. Department of Justice; 2005. Karberg JC, James DJ. Substance dependence, abuse, and treatment of jail inmates, 2002. Washington DC: U.S. Department of Justice; 2005.
5.
go back to reference Boutwell AE, Nijhawan A, Zaller N, Rich JD. Arrested on heroin: a national opportunity. J Opioid Manag. 2007;3:328–32.PubMed Boutwell AE, Nijhawan A, Zaller N, Rich JD. Arrested on heroin: a national opportunity. J Opioid Manag. 2007;3:328–32.PubMed
6.
go back to reference Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301:183–90.PubMedCentralPubMedCrossRef Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301:183–90.PubMedCentralPubMedCrossRef
7.
go back to reference Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–42.PubMedCentralPubMedCrossRef Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103:1333–42.PubMedCentralPubMedCrossRef
8.
go back to reference Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159:592–600.PubMedCrossRef Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159:592–600.PubMedCrossRef
9.
go back to reference Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356:157–65.PubMedCentralPubMedCrossRef Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356:157–65.PubMedCentralPubMedCrossRef
10.
go back to reference Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
11.
go back to reference Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515–32.PubMedCrossRef Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515–32.PubMedCrossRef
12.
go back to reference Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105:83–8.PubMedCentralPubMedCrossRef Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105:83–8.PubMedCentralPubMedCrossRef
13.
go back to reference Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82:411–9.PubMedCentralPubMedCrossRef Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005;82:411–9.PubMedCentralPubMedCrossRef
14.
go back to reference Lee JD, Rich JD. Opioid pharmacotherapy in criminal justice settings: now is the time. Subst Abus. 2012;33:1–4.PubMedCrossRef Lee JD, Rich JD. Opioid pharmacotherapy in criminal justice settings: now is the time. Subst Abus. 2012;33:1–4.PubMedCrossRef
15.
go back to reference The Correctional Association of New York. Treatment behind bars: substance abuse treatment in New York prisons, 2007–2010. New York: The Correctional Association of New York; 2011. The Correctional Association of New York. Treatment behind bars: substance abuse treatment in New York prisons, 2007–2010. New York: The Correctional Association of New York; 2011.
16.
go back to reference Simpler AH, Langhinrichsen-Rohling J. Substance use in prison: how much occurs and is it associated with psychopathology? Addiction Research & Theory. 2005;13:503–11.CrossRef Simpler AH, Langhinrichsen-Rohling J. Substance use in prison: how much occurs and is it associated with psychopathology? Addiction Research & Theory. 2005;13:503–11.CrossRef
17.
go back to reference Nurco DJ, Hanlon TE, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behav Sci Law. 1991;9:221–42.CrossRef Nurco DJ, Hanlon TE, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behav Sci Law. 1991;9:221–42.CrossRef
18.
go back to reference Belenko S. Assessing released inmates for substance-abuse-related service needs. Crime & Delinquency. 2006;52:94–113.CrossRef Belenko S. Assessing released inmates for substance-abuse-related service needs. Crime & Delinquency. 2006;52:94–113.CrossRef
19.
go back to reference Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100:820–8.PubMedCrossRef Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100:820–8.PubMedCrossRef
20.
go back to reference Garcia CA, Correa GC, Viver AD, Kinlock TW, Gordon MS, Avila CA, et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addict Med. 2007;1:126–32.PubMedCrossRef Garcia CA, Correa GC, Viver AD, Kinlock TW, Gordon MS, Avila CA, et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addict Med. 2007;1:126–32.PubMedCrossRef
21.
go back to reference Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav. 2008;35:34–47.PubMedCentralPubMedCrossRef Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav. 2008;35:34–47.PubMedCentralPubMedCrossRef
22.
go back to reference Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99:222–30.PubMedCentralPubMedCrossRef Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99:222–30.PubMedCentralPubMedCrossRef
23.
go back to reference Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40.PubMedCrossRef Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40.PubMedCrossRef
24.
go back to reference McMillan GP, Lapham S, Lackey M. The effect of a jail methadone maintenance therapy (MMT) program on imate recidivism. Addiction. 2008;103:2017–23.PubMedCrossRef McMillan GP, Lapham S, Lackey M. The effect of a jail methadone maintenance therapy (MMT) program on imate recidivism. Addiction. 2008;103:2017–23.PubMedCrossRef
25.
go back to reference Magura S, Rosenblum A, Lewis C, Joseph H. Effectiveness of in-jail methadone maintenance. J Drug Issues. 1993;23:75–99. Magura S, Rosenblum A, Lewis C, Joseph H. Effectiveness of in-jail methadone maintenance. J Drug Issues. 1993;23:75–99.
26.
go back to reference van Olphen J, Freudenberg N, Fortin P, Galea S. Community reentry: perceptions of people with substance use problems returning home from New York City jails. J Urban Health. 2006;83:372–81.PubMedCentralPubMedCrossRef van Olphen J, Freudenberg N, Fortin P, Galea S. Community reentry: perceptions of people with substance use problems returning home from New York City jails. J Urban Health. 2006;83:372–81.PubMedCentralPubMedCrossRef
27.
go back to reference Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.PubMedCentralPubMedCrossRef Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.PubMedCentralPubMedCrossRef
28.
go back to reference Binswanger IA, Nowels C, Corsi KF, Long J, Booth RE, Kutner J, et al. “From the prison door right to the sidewalk, everything went downhill”, a qualitative study of the health experiences of recently released inmates. Int J Law Psychiatry. 2011;34:249–55.PubMedCrossRef Binswanger IA, Nowels C, Corsi KF, Long J, Booth RE, Kutner J, et al. “From the prison door right to the sidewalk, everything went downhill”, a qualitative study of the health experiences of recently released inmates. Int J Law Psychiatry. 2011;34:249–55.PubMedCrossRef
29.
go back to reference Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003;70:S29–37.PubMedCrossRef Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003;70:S29–37.PubMedCrossRef
30.
go back to reference Kinlock TW, Gorden MS, Schwartz RP, Fitzgerald TT. Developing and implementing a new prison-based buprenorphine treatment program. J Offender Rehabil. 2010;49:91–109.PubMedCentralPubMedCrossRef Kinlock TW, Gorden MS, Schwartz RP, Fitzgerald TT. Developing and implementing a new prison-based buprenorphine treatment program. J Offender Rehabil. 2010;49:91–109.PubMedCentralPubMedCrossRef
31.
go back to reference Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949–58.PubMedCrossRef Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949–58.PubMedCrossRef
32.
go back to reference Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39:96–104.PubMedCrossRef Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39:96–104.PubMedCrossRef
33.
go back to reference Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1:62–7.PubMedCrossRef Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1:62–7.PubMedCrossRef
34.
go back to reference Cunningham JA, Sobell LC, Sobell MB, Agrawal S, Toneatto T. Barriers to treatment: why alcohol and drug abusers delay or never seek treatment. Addict Behav. 1993;18:347–53.PubMedCrossRef Cunningham JA, Sobell LC, Sobell MB, Agrawal S, Toneatto T. Barriers to treatment: why alcohol and drug abusers delay or never seek treatment. Addict Behav. 1993;18:347–53.PubMedCrossRef
35.
go back to reference Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients’ reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4:204–10.PubMedCentralPubMedCrossRef Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients’ reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4:204–10.PubMedCentralPubMedCrossRef
36.
go back to reference Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs. 2010;42:339–46.PubMedCentralPubMedCrossRef Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs. 2010;42:339–46.PubMedCentralPubMedCrossRef
37.
go back to reference Cunningham C, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40:500–6.PubMedCentralPubMed Cunningham C, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40:500–6.PubMedCentralPubMed
38.
go back to reference Fox AD, Anderson MR, Bartlett G, Valverde J, MacDonald RF, Shapiro LI, et al. A description of an urban transitions clinic serving formerly incarcerated persons. J Health Care Poor Underserved. 2014;25:376–82.PubMedCentralPubMedCrossRef Fox AD, Anderson MR, Bartlett G, Valverde J, MacDonald RF, Shapiro LI, et al. A description of an urban transitions clinic serving formerly incarcerated persons. J Health Care Poor Underserved. 2014;25:376–82.PubMedCentralPubMedCrossRef
39.
40.
go back to reference Fox AD, Shah PA, Sohler NL, Lopez CM, Starrels JL, Cunningham CO. I heard about it from a friend: assessing interest in buprenorphine treatment. Subst Abus. 2014;35:74–9.PubMedCentralPubMedCrossRef Fox AD, Shah PA, Sohler NL, Lopez CM, Starrels JL, Cunningham CO. I heard about it from a friend: assessing interest in buprenorphine treatment. Subst Abus. 2014;35:74–9.PubMedCentralPubMedCrossRef
41.
go back to reference Shah PA, Sohler NL, Lopez C, Fox AD, Cunningham CO. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program. J Opioid Manag. 2013;9:407–13.PubMedCentralPubMedCrossRef Shah PA, Sohler NL, Lopez C, Fox AD, Cunningham CO. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program. J Opioid Manag. 2013;9:407–13.PubMedCentralPubMedCrossRef
42.
go back to reference Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584–9.PubMedCentralPubMedCrossRef Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584–9.PubMedCentralPubMedCrossRef
43.
go back to reference Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder–and its treatment. JAMA. 2014;311:1393–4.PubMedCrossRef Olsen Y, Sharfstein JM. Confronting the stigma of opioid use disorder–and its treatment. JAMA. 2014;311:1393–4.PubMedCrossRef
44.
go back to reference Mitchell SG, Kelly SM, Brown BS, Reisinger HS, Peterson JA, Ruhf A, et al. Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs. 2009;41:145–52.PubMedCentralPubMedCrossRef Mitchell SG, Kelly SM, Brown BS, Reisinger HS, Peterson JA, Ruhf A, et al. Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs. 2009;41:145–52.PubMedCentralPubMedCrossRef
45.
go back to reference Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–8.PubMedCentralPubMedCrossRef Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–8.PubMedCentralPubMedCrossRef
46.
go back to reference Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108:1628–37.PubMedCrossRef Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108:1628–37.PubMedCrossRef
47.
go back to reference Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005;79:351–7.PubMedCentralPubMedCrossRef Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend. 2005;79:351–7.PubMedCentralPubMedCrossRef
48.
go back to reference Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat. 2008;35:116–24.PubMedCrossRef Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat. 2008;35:116–24.PubMedCrossRef
49.
go back to reference Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33:48–59.PubMedCentralPubMedCrossRef Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33:48–59.PubMedCentralPubMedCrossRef
Metadata
Title
Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder
Authors
Aaron D Fox
Jeronimo Maradiaga
Linda Weiss
Jennifer Sanchez
Joanna L Starrels
Chinazo O Cunningham
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Addiction Science & Clinical Practice / Issue 1/2015
Electronic ISSN: 1940-0640
DOI
https://doi.org/10.1186/s13722-014-0023-0

Other articles of this Issue 1/2015

Addiction Science & Clinical Practice 1/2015 Go to the issue